Donate For Public and Patients Store Search

F053 - Unmasking Facial Pigmentation

Saturday, March 2; 9:00 AM - 11:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • List the differential diagnosis of facial pigmentation
  • Recognize the clinical features that distinguish melasma from other common causes of facial pigmentation
  • 3. Describe uncommon causes of facial pigmentation 4. Describe new medical and laser advances in the treatment of facial pigmentation

Description

As the world becomes more diverse, dermatologists are seeing and treating more patients with pigmentary disorders. This session will review the clinical features and pathogenesis of melasma, post-inflammatory hyperpigmentation, acquired dermal melanosis and other less common pigmentary disorders. Attention will be given to exciting new therapeutic medical and laser options used to treat facial pigmentation. The interactive format will provide time for questions and discussion of clinical cases.

Disclosures

  • Pandya, Amit G., MD: Aclaris Therapeutics Inc. – I(Grants/Research Funding); Clarify Medical Inc. – B(ST); Incyte Corporation – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding);
  • Passeron, Thierry, MD, PhD: AbbVie – A(H), Speaker/Faculty Education(H); Astellas Pharma US, Inc – I(Grants/Research Funding); Beiersdorf, Inc. – SP(H); Bioderma – Speaker/Faculty Education(H); Celgene Corporation – I(Grants/Research Funding); Galderma Research & Development, LLC – A(H); GlaxoSmithKline – Speaker/Faculty Education(H); ISDIN – A(H), SP(H); Janssen-Cilag – A(H), Speaker/Faculty Education(H); Journal of the European Academy of Dermatology and Venereology – O(NC); L'OrĂ©al Research and Innovation – Speaker/Faculty Education(H); La Roche-Posay Laboratorie Pharmaceutique – Speaker/Faculty Education(H); Lancome – C(H); Leo Pharma Inc. – Speaker/Faculty Education(H); Lilly ICOS LLC – Speaker/Faculty Education(H); MSD – A(H); Novartis – A(H), SP(H); Pfizer Inc. – A(H); Sanofi – A(H); Symrise – A(H); Syneron Candela – Speaker/Faculty Education(H);
  • Rodrigues, Michelle, MBBS: Cynosure, Inc. – A(NC); La Roche-Posay Laboratorie Pharmaceutique – Speaker/Faculty Education(H);
  • Tanghetti, Emil A., MD: Accure Medical, LLC – I(Grants/Research Funding); Allergan, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); Amgen – I(Grants/Research Funding); Bayer – SP(H); Celgene Corporation – I(Grants/Research Funding); Coherus Biosciences – I(Grants/Research Funding); Cynosure, Inc. – C(EQ), I(EQ); DUSA Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding), SP(H); Galderma Research & Development, LLC – C(H), I(Grants/Research Funding), SP(H); Leo Pharma A/S – I(Grants/Research Funding); Leo Pharma Inc – SP(H); Lilly ICOS LLC – I(Grants/Research Funding); Valeant Pharmaceuticals International – I(Grants/Research Funding), SP(H);
Schedule
Saturday, March 2
9:00 AM
Dr. Rodrigues / An approach to the diagnosis of facial pigmentation
9:30 AM
Dr. Pandya / Uncommon causes of facial pigmentation
10:10 AM
Passeron / Medical treatment for pigmentation: What's new?
10:35 AM
Dr. Tanghetti / Laser treatment for facial pigmentation - What's new?
Event Details
  • Date
    Saturday, March 2
  • Time
    9:00 AM - 11:00 AM
  • Location
    Room 202A
  • CME Credits
    2.00
  • Type
    New
Directors/Co-Directors
Speakers